Metal Ion Concentration Between Coated and Uncoated TKA

January 28, 2020 updated by: Technische Universität Dresden

Metal Ion Concentration and Clinical Outcome Between Coated and Uncoated TKA

Metal ion release from metal implants may have side effects. It can be reduced by coating of the implant. This study compares coated and uncoated TKA.

Study Overview

Detailed Description

Patients are randomized to receive a coated or uncoated TKA. Patients are assessed before surgery, after 3 month, 1 year and 5 years.

Blood samples are collected in 7.5 ml S-Monovette® tubes (for trace metal analysis, Sarstedt AG, Germany) using a specific steel needle for trace metal analysis (Sarstedt AG, Germany). Within one hour, plasma was separated by centrifugation at 2500g for ten minutes. Samples were stored at -20°C before being analysed for chromium, cobalt, molybdenum and nickel content using a graphite furnace atomic absorption spectrometer Z-8270 with Polarisation-Zeeman-Absorption (Hitachi Ltd., Japan). The accuracy and precision of the method is validated to < 10% using the control materials SeronormTM Trace Elements Serum (SERO AS, Norway). The detection limit of the method is estimated at 0.5µg/l for chromium, cobalt and molybdenum, 1.0µg/l for nickel (mean + 3 standard deviations from buffer). All probes having ion levels below the detection limit were adjusted to 0.25µg/l for chromium, cobalt and molybdenum and 0.5µg/l for nickel.

Clinical outcome is measured with the Knee Society Score, Oxford Knee Score, Short-Form 36 and University of Los Angeles Activity Score.

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • indication to TKA
  • no other metal implant

Exclusion Criteria:

  • no informed consent
  • not able to understand study and/or questionnaires
  • Need of a higher constrained implant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Coated Total Knee Arthroplasty
Implantation of a coated Total Knee Arthroplasty
Implantation of a coated Total Knee Arthroplasty
Active Comparator: Standard Total Knee Arthroplasty
Implantation of a Standard Total Knee Arthroplasty
Implantation of a Standard Total Knee Arthroplasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Metal Ions (Cobalt, Chromium, Molydenum, Nickel)
Time Frame: before surgery, 1 year, 5 years
Change in Serum Metal Ion concentrations 1 and 5 years after surgery
before surgery, 1 year, 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Function
Time Frame: before surgery, 3 month, 1 year, 5 years
Knee Society Score
before surgery, 3 month, 1 year, 5 years
Patient Reported Outcome
Time Frame: before surgery, 3 month, 1 year, 5 years
Oxford Knee Score
before surgery, 3 month, 1 year, 5 years
Health-related Quality of Life
Time Frame: before surgery, 3 month, 1 year, 5 years
SF 36
before surgery, 3 month, 1 year, 5 years
Activity
Time Frame: before surgery, 3 month, 1 year, 5 years
UCLA activity score
before surgery, 3 month, 1 year, 5 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Events
Time Frame: through study completion, in average 5 years
Adverse Events
through study completion, in average 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Jörg Lützner, MD, University Hospital Carl Gustav Carus

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2012

Primary Completion (Actual)

February 28, 2015

Study Completion (Anticipated)

December 1, 2020

Study Registration Dates

First Submitted

January 24, 2017

First Submitted That Met QC Criteria

February 6, 2017

First Posted (Estimate)

February 9, 2017

Study Record Updates

Last Update Posted (Actual)

January 29, 2020

Last Update Submitted That Met QC Criteria

January 28, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Osteoarthritis

Clinical Trials on Coated Total Knee Arthroplasty

3
Subscribe